PDF(Pubmed)
Abstract：
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are widely recognised as being able to induce a potent reduction in low‑density lipoprotein‑cholesterol. An increasing number of studies have suggested that PCSK9 also influences the haemostatic system by altering platelet function and the coagulation cascade. These findings have significant implications for anti‑PCSK9 therapy in patients with specific coagulation conditions, including expanded indications, dose adjustments and drug interactions. The present review summarises the changes in PCSK9 levels in individuals with liver diseases, chronic kidney diseases, diabetes mellitus, cancer and other disease states, and discusses their impact on thrombosis and haemostasis. Furthermore, the structure, effects and regulatory mechanisms of PCSK9 on platelets, coagulation factors, inflammatory cells and endothelial cells during coagulation and haemostasis are described.
摘要：
前蛋白转化酶枯草杆菌蛋白酶kexin9型（PCSK9）抑制剂被广泛认为能够诱导低密度脂蛋白胆固醇的有效降低。越来越多的研究表明，PCSK9还通过改变血小板功能和凝血级联反应来影响止血系统。这些发现对特定凝血状况患者的抗PCSK9治疗具有重要意义。包括扩大的适应症，剂量调整和药物相互作用。本综述总结了肝脏疾病患者PCSK9水平的变化。慢性肾脏疾病,糖尿病,癌症和其他疾病状态，并讨论了它们对血栓形成和止血的影响。此外，结构,PCSK9对血小板的影响和调节机制，凝血因子，描述了凝血和止血过程中的炎症细胞和内皮细胞。
